title: Commentary on: everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.
authors: Department of Urological Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
authors: Peter
authors: P
authors: Black
mesh_terms: D018207:Angiomyolipoma / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D020123:Sirolimus / Q000031:analogs & derivatives*
chemical_list: D000970:Antineoplastic Agents; D020123:Sirolimus